With the successful launch of the inaugural issue of *JACC: Basic to Translational Science* on March 2, 2016, and the accompanying statement from the editors outlining the rationale and goals for the journal [@bib1], it is timely, if not appropriate, for the second Editor's Page to focus on orienting our readers to the planned thematic content for *JACC: Basic to Translational Science*, and more importantly, to provide a glimpse of where the journal is heading in the future.

One of the major goals for *JACC: Basic to Translational Science* is to become a forum and learning center for translational cardiovascular investigators in academia and industry, patients and families affected by heart disease, the National Heart, Lung, and Blood Institute, and the U.S. Food and Drug Administration (FDA). To this end, each issue of *JACC: Basic to Translational Science* will have a State-of-the-Art Review that summarizes research themes that are both timely and cutting-edge, but that also address novel research questions that bridge the gap between basic science and clinical science. In the current issue, the State-of-the-Art Review summarizes the recent spate of "neutral" clinical trials that have plagued device-based therapies that seek to modulate the autonomic nervous system in heart failure patients [@bib2]. The review concludes by discussing several of the reasons why it has been so difficult to move neuromodulatory therapies from animal models into successful phase II/III clinical trials.

*JACC: Basic to Translational Science* will also feature a special content area referred to as the "Translational Toolbox." The papers in the toolbox are intended to orient investigators to the various regulatory issues that they will face when bringing their ideas from the bench to the bedside, as well as inform investigators how to obtain funding for their translational research efforts. For example, the first issue featured an excellent paper by Christopher Colecchi and David Tancredi on how the Leducq Foundation is funding translational cardiovascular research through the creation of Broadview Ventures, which promotes the development of technology for the diagnosis and treatment of cardiovascular disease and stroke through direct, equity-based investments [@bib3]. Subsequent related features in the toolbox will include papers on funding opportunities provided by venture capitalists as well as the National Institutes of Health. With respect to serving as a learning center for translational investigators, the current issue of *JACC: Basic to Translational Science* features the first of a 2-part series by Dr. Gail Van Norman that focuses on understanding the basics of the FDA approval process for drugs [@bib4]. This will be followed by a second themed review paper on the FDA approval process for devices. For basic investigators who are unfamiliar with the regulatory approval process, these 2 papers are a must read!

In an attempt to create a forum for discussions dedicated to developing new cardiovascular therapies, beginning with the current issue, *JACC: Basic to Translational Science* will also feature a section entitled "Translational Perspectives." The vision for this section is to create a mashup of Hyde Park sessions, the more traditional Letter to the Editors section (albeit longer), as well as au courant summaries of trending issues in academia, industry, FDA, and National Institutes of Health. As 1 example, in the current issue, Bristow et al. [@bib5] discuss issues related to geographic inhomogeneity in patient recruitment in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial [@bib6], and review how they may have negatively influenced the primary endpoint of the trial. More importantly, the authors provide guidance for how to avoid similar types of problems in future multinational trials.
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===================================================

The editors are committed to creating a journal that focuses on accelerating the translation of new scientific discoveries into new therapies that improve meaningful clinical outcomes for patients with cardiovascular disease. Clearly this cannot happen in a vacuum. Where *JACC: Basic to Translational Science* goes in the future will depend on the needs and interests of investigators in academia and industry, patients, societies, and all of the governmental regulatory agencies, all of whom we seek to engage collaboratively in an effort to improve the health of patients with heart and vascular disease. Please let us know how we are doing and what you would like to see in *JACC: Basic to Translational Science*. You can share your thoughts about the thematic content through social media (*\#JACCBTSQuoVadis*) or by e-mail (<jaccbts@acc.org>).
